| II-035 Rasmus Henninger Preclinical population pharmacokinetic modelling of skin target site exposure of DNDI-0690 and DNDI-6148 in the treatment of cutaneous leishmaniasis Wednesday 15:20-16:50 |
| II-035 Rasmus Henninger Preclinical population pharmacokinetic modelling of skin target site exposure of DNDI-0690 and DNDI-6148 in the treatment of cutaneous leishmaniasis Wednesday 15:20-16:50 |